journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://read.qxmd.com/read/30763444/evaluating-risks-and-benefits-of-evolving-systemic-treatments-of-neuroendocrine-tumors
#1
Jonathan Raphael Strosberg, Taymeyah Al-Toubah, Mauro Cives
No abstract text is available yet for this article.
February 14, 2019: JAMA Oncology
https://read.qxmd.com/read/30763443/error-in-figure
#2
(no author information available yet)
No abstract text is available yet for this article.
February 14, 2019: JAMA Oncology
https://read.qxmd.com/read/30763442/role-of-monthly-high-dose-vitamin-d-supplementation-in-cancer-prevention
#3
Craig Davidson Peiris, Sarah Jaroudi, Theresa Byrd
No abstract text is available yet for this article.
February 14, 2019: JAMA Oncology
https://read.qxmd.com/read/30763440/role-of-monthly-high-dose-vitamin-d-supplementation-in-cancer-prevention-in-reply
#4
Robert Scragg, Carlos A Camargo
No abstract text is available yet for this article.
February 14, 2019: JAMA Oncology
https://read.qxmd.com/read/30763436/therapeutic-options-for-neuroendocrine-tumors-a-systematic-review-and-network-meta-analysis
#5
Reto M Kaderli, Marko Spanjol, Attila Kollár, Lukas Bütikofer, Viktoria Gloy, Rebecca A Dumont, Christian A Seiler, Emanuel R Christ, Piotr Radojewski, Matthias Briel, Martin A Walter
Importance: Multiple therapies are currently available for patients with neuroendocrine tumors (NETs), yet many therapies have not been compared head-to-head within randomized clinical trials (RCTs). Objective: To assess the relative safety and efficacy of therapies for NETs. Data Sources: PubMed, Embase, the Cochrane Central Register of Controlled Trials, trial registries, meeting abstracts, and reference lists from January 1, 1947, to March 2, 2018, were searched...
February 14, 2019: JAMA Oncology
https://read.qxmd.com/read/30763430/trends-in-smoking-and-e-cigarette-use-among-us-patients-with-cancer-2014-2017
#6
Nina N Sanford, David J Sher, Xiaohan Xu, Ayal A Aizer, Brandon A Mahal
No abstract text is available yet for this article.
February 14, 2019: JAMA Oncology
https://read.qxmd.com/read/30763425/quality-of-life-in-patients-with-low-risk-prostate-cancer-treated-with-hypofractionated-vs-conventional-radiotherapy-a-phase-3-randomized-clinical-trial
#7
Deborah W Bruner, Stephanie L Pugh, W Robert Lee, James J Dignam, Daniel Low, Gregory P Swanson, Amit B Shah, Shawn Malone, Jeff M Michalski, Ian S Dayes, Samantha A Seaward, Paul L Nguyen, William A Hall, Thomas M Pisansky, Yuhchyau Chen, Howard M Sandler, Benjamin Movsas
Importance: Hypofractionated radiotherapy (HRT) would be more convenient for men with low-risk prostate cancer and cost less than conventional radiotherapy (CRT) as long as HRT is noninferior to CRT in terms of survival and quality of life (QOL) is not found to be worse. Objective: To assess differences in QOL between men with low-risk prostate cancer who are treated with HRT vs CRT. Design, Setting, and Participants: In this phase 3 randomized clinical trial, men with low-risk prostate cancer were enrolled from sites within the National Cancer Institute's National Clinical Trials Network in the United States, Canada, and Switzerland...
February 14, 2019: JAMA Oncology
https://read.qxmd.com/read/30763415/pentito
#8
Gregory A Abel
No abstract text is available yet for this article.
February 14, 2019: JAMA Oncology
https://read.qxmd.com/read/30730555/questioning-lay-health-worker-influence-on-goals-of-care-documentation-and-patient-satisfaction
#9
Nicholas Yew Wei Heng, Thineskrishna Anbarasan
No abstract text is available yet for this article.
February 7, 2019: JAMA Oncology
https://read.qxmd.com/read/30730554/time-for-advance-care-planning-discussions-during-transitions-in-care-in-cancer-clinical-trials
#10
Connie M Ulrich, Christine Grady
No abstract text is available yet for this article.
February 7, 2019: JAMA Oncology
https://read.qxmd.com/read/30730552/prevalence-of-germline-variants-in-prostate-cancer-and-implications-for-current-genetic-testing-guidelines
#11
Piper Nicolosi, Elisa Ledet, Shan Yang, Scott Michalski, Brandy Freschi, Erin O'Leary, Edward D Esplin, Robert L Nussbaum, Oliver Sartor
Importance: Prostate cancer is the third leading cause of cancer-related death in men in the United States. Although serious, most of these diagnoses are not terminal. Inherited risk for prostate cancer is associated with aggressive disease and poorer outcomes, indicating a critical need for increased genetic screening to identify disease-causing variants that can pinpoint individuals at increased risk for metastatic castration-resistant prostate cancer. Objective: To identify positive (pathogenic, likely pathogenic, and increased risk) germline variants in a large prostate cancer cohort and to evaluate the usefulness of current practice guidelines in recognizing individuals at increased risk for prostate cancer who would benefit from diagnostic genetic testing...
February 7, 2019: JAMA Oncology
https://read.qxmd.com/read/30730550/questioning-lay-health-worker-influence-on-goals-of-care-documentation-and-patient-satisfaction-in-reply
#12
Manali I Patel
No abstract text is available yet for this article.
February 7, 2019: JAMA Oncology
https://read.qxmd.com/read/30730549/safety-and-efficacy-of-immune-checkpoint-inhibitor-therapy-in-patients-with-hiv-infection-and-advanced-stage-cancer-a-systematic-review
#13
Michael R Cook, Chul Kim
Importance: Patients with HIV infection are at increased risk for cancer. Cancer is the leading cause of death among non-AIDS-defining illnesses in these patients. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of cancer. However, clinical trials of ICIs have historically excluded patients with HIV infection. The safety and efficacy profile of ICIs is unknown in this underrepresented population. Objective: To summarize results on the safety and efficacy of ICI therapy in HIV-infected patients with advanced-stage cancer...
February 7, 2019: JAMA Oncology
https://read.qxmd.com/read/30730547/triassic-cancer-osteosarcoma-in-a-240-million-year-old-stem-turtle
#14
Yara Haridy, Florian Witzmann, Patrick Asbach, Rainer R Schoch, Nadia Fröbisch, Bruce M Rothschild
No abstract text is available yet for this article.
February 7, 2019: JAMA Oncology
https://read.qxmd.com/read/30730546/effect-of-laparoscopic-distal-gastrectomy-vs-open-distal-gastrectomy-on-long-term-survival-among-patients-with-stage-i-gastric-cancer-the-klass-01-randomized-clinical-trial
#15
Hyung-Ho Kim, Sang-Uk Han, Min-Chan Kim, Wook Kim, Hyuk-Joon Lee, Seung Wan Ryu, Gyu Seok Cho, Chan Young Kim, Han-Kwang Yang, Do Joong Park, Kyo Young Song, Sang-Il Lee, Seong Yeob Ryu, Joo-Ho Lee, Woo Jin Hyung
Importance: Laparoscopic distal gastrectomy is gaining popularity over open distal gastrectomy for gastric cancer because of better early postoperative outcomes. However, to our knowledge, no studies have proved whether laparoscopic distal gastrectomy is oncologically equivalent to open distal gastrectomy. Objective: To examine whether the long-term survival among patients with stage I gastric cancer undergoing laparoscopic distal gastrectomy is noninferior to that among patients undergoing open distal gastrectomy...
February 7, 2019: JAMA Oncology
https://read.qxmd.com/read/30730531/pruritic-rash-in-a-woman-with-hodgkin-lymphoma
#16
Clayton Jackson, Lindsey Strowd, Zanetta Lamar
No abstract text is available yet for this article.
February 7, 2019: JAMA Oncology
https://read.qxmd.com/read/30703213/biospecimens-research-consent-and-distinguishing-cell-line-research
#17
Kayte Spector-Bagdady, Holly Fernandez Lynch, J Chad Brenner, Andrew G Shuman
Newly revised regulations for human research affecting translational oncology will become effective in January 2019. A substantial component of the debate leading to this revision was how to regulate biospecimen research; specifically, whether all biospecimens should be considered inherently "identifiable," thereby necessitating informed consent for use in research. The famous cases seminal to this discussion involve cancer cell lines, but the unique features of this kind of biospecimen research were largely missing from the regulatory deliberation...
January 31, 2019: JAMA Oncology
https://read.qxmd.com/read/30703207/the-best-medicine
#18
Gregory A Abel
No abstract text is available yet for this article.
January 31, 2019: JAMA Oncology
https://read.qxmd.com/read/30703192/derivation-of-anthracycline-and-anthraquinone-equivalence-ratios-to-doxorubicin-for-late-onset-cardiotoxicity
#19
Elizabeth A M Feijen, Wendy M Leisenring, Kayla L Stratton, Kirsten K Ness, Helena J H van der Pal, Elvira C van Dalen, Gregory T Armstrong, Gregory J Aune, Daniel M Green, Melissa M Hudson, Jacqueline Loonen, Kevin C Oeffinger, Leslie L Robison, Yutaka Yasui, Leontien C M Kremer, Eric J Chow
Importance: Anthracyclines are part of many effective pediatric cancer treatment protocols. Most pediatric oncology treatment groups assume that the hematologic toxicity of anthracycline agents is equivalent to their cardiotoxicity; for example, Children's Oncology Group substitution rules consider daunorubicin and epirubicin isoequivalent to doxorubicin, whereas mitoxantrone and idarubicin are considered 4 to 5 times as toxic as doxorubicin. Objective: To determine optimal dose equivalence ratios for late-onset cardiomyopathy between doxorubicin and other anthracyclines or the anthraquinone mitoxantrone...
January 31, 2019: JAMA Oncology
https://read.qxmd.com/read/30703190/effect-of-adding-docetaxel-to-androgen-deprivation-therapy-in-patients-with-high-risk-prostate-cancer-with-rising-prostate-specific-antigen-levels-after-primary-local-therapy-a-randomized-clinical-trial
#20
Stéphane Oudard, Igor Latorzeff, Armelle Caty, Laurent Miglianico, Emmanuel Sevin, Anne Claire Hardy-Bessard, Remy Delva, Frédéric Rolland, Loic Mouret, Franck Priou, Philippe Beuzeboc, Gwenaelle Gravis, Claude Linassier, Philippe Gomez, Eric Voog, Xavier Muracciole, Christine Abraham, Eugeniu Banu, Jean-Marc Ferrero, Alain Ravaud, Ivan Krakowski, Jean-Léon Lagrange, Gaël Deplanque, David Zylberait, Laurence Bozec, Nadine Houede, Stéphane Culine, Reza Elaidi
Importance: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective: To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific antigen (PSA) levels after primary local therapy and high-risk factors but no evidence of metastatic disease. Design, Setting, and Participants: This open-label, phase 3, randomized superiority trial comparing ADT plus docetaxel vs ADT alone enrolled patients from 28 centers in France between June 4, 2003, and September 25, 2007; final follow-up was conducted April 12, 2017, and analysis was performed May 2 to July 31, 2017...
January 31, 2019: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"